Retinal Diagnostic Department,
Diode lasers have a number of advantages over other laser systems. There are no requirements for either an ancillary cooling system or a three phase electricity supply. In VA at last visit 6/36 0 6/36 0 6/6 0 CF -6/9 0 6/9 0 6/9 0 6/9 0 6/6 0 6/9 + 6/18 0 6/9 0 6/60 0 6/36 0 6/9 0 6/6 0 6/6 0 6/12 0 6/5 + 6/5 0 6/12 0 6/9 0 6/18 0 6/9 0 6/9 0 6/9 0 6/9 0 6/12 0 6/6 0 6/9 0 6/6 0 6/6 0 6/5 + period of this pilot study was rather short; however, a follow up of 4 months is generally considered sufficient after argon laser treatment for macular oedema. Moreover Currently, the preferred technique for laser treatment of clinically significant diabetic macular oedema is to focally irradiate leaking retinal microaneurysms with argon laser radiation. The underlying concept in such photocoagulation treatment is that closure of these discrete sources of leakage results in eventual resorption of hard exudates and resolution of retinal thickening.
The employment of a laser system emitting in the red or infrared spectrum correlated with a protocol demanding focal irradiation of retinal microaneurysms may seem illogical, as even less radiation at 810 nm will be absorbed within microaneurysms than at krypton red (647 nm). In argon laser irradiation, if the microaneurysm is large, then significant amounts of energy will be focally deposited within the abnormal vessel and the resulting thermal gradients may produce an acute thrombosis. Clinically, this is frequently observed as the vascular lesion changes colour from red to greyish white. In krypton or diode treatment, the transparency of the vascular lesion to this wavelength precludes the generation of significant thermal disturbance in the retinal microaneurysm and therefore acute spasms or thrombosis were not observed in this study. However, in eyes with clinically significant macular oedema, as in the current study, at review 3 months after treatment, many retinal microaneurysms within the area of focal treatment had resolved together with partial or complete resorption of retinal thickening. This was finally observed in 27 of 33 eyes treated. A similar clinical response has been reported in patients treated with a krypton or dye-red laser in a grid pattern for diffuse diabetic macular oedema.15 16 Laboratory studies employing tissue culture techniques on both human retinal pigment epithelial cells and retinal capillary endothelial cells are beginning to demonstrate possible biochemical mediators which induce beneficial tissue responses secondary to photocoagulation.17 18 A clinicopathological study tends to confirm the concept that closure of retinal microaneurysms is not due to direct absorption of laser energy within the lesion. Wallow and Bindley performed histological examination on a human retina that had been given focal photocoagulation for diabetic macular oedema. It was found that the majority of retinal bums involved the retinal pigment epithelium and photoreceptor layer. In all but a few heavy bums, there was sparing of the inner nuclear layer, within which microaneurysms tend to be located. It was observed, however, the focal photocoagulation had resulted in successful closure of many of the microvascular lesions.21 It therefore appears to be likely that the current protocol in relation to focal macular photocoagulation demands power levels in excess of those necessary to produce the desired therapeutic effect.
In conclusion, photocoagulation with near infrared wavelength may have a number ofbiophysical advantages over treatment with laser radiation of shorter wavelengths. There is better transmission through media opacitiesfor example, nuclear sclerotic cataracts, and during treatment the patient is not irritated by bright flashes. In macular treatment there is no extra pain compared with the argon laser.3 22 By historical comparison, in this initial pilot study the diode laser was equally effective in the treatment of clinically significant diabetic macular oedema as the established argon laser system.
